Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: burner who wrote (77)	12/27/1998 5:46:00 PM
From: burner	Respond to of 134

IMMUNE NETWORK RESEARCH LTD. IMM : VSE NewsNOW! Automatic E-mail Alert Monday, December 21, 1998 NEWS RELEASE: ANTIBODY PATENT ISSUED VANCOUVER, BC - Victor Jones, President, is very pleased to report that the United States Patent Office has issued a patent covering monoclonal antibody 1F7 ("mAb 1F7") as United States Patent No. 5,849,583 titled Anti-idiotypic Antibody And Its Use In Diagnosis And Therapy In HIV-Related Disease. The patent office abstract states-, "The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds". The Company has licensed mAb 1F7 from the Sydney Kimmel Cancer Centre and is conducting pre-clinical studies on macaques, which are a biological model for HIV disease in humans. The Company may file divisional applications in respect of certain additional claims not allowed under the patent just issued. The Company is waiting on responses from two laboratories in respect of bioassays on blood plasma prior to selection of the laboratory to analyze all of the plasma samples taken during its six month Phase II pre-clinical trial of mAb 1F7. This study was designed to evaluate the beneficial effects of mAb 1F7 on levels of SHIV virus in the macaques and to test different SHIV clones. In an earlier study, mAb 1F7 was shown to both strengthen and broaden the immune response against the viral infection in the monkeys. Data from this study will be integral to the application to the FDA for approval of a human trial of mAb 1F7 under an Investigational New Drug protocol, which is the next milestone. The Company has closed a previously announced private placement at $45,000 and will prepare for further financing in 1999 giving consideration to the patent just issued for mAb 1F7 and anticipated results from the Phase 11 Pre-clinical Study. "signed" Victor J.E. Jones President Immune Network Research Ltd. 900 - 475 Howe Street Vancouver, B.C., Canada V6C 2B3 Tel. (604) 689-3923 Fax. (604) 684-5854 immunenetwork.com The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. ----------------------- You received this message because you are registered as a member of INR's NewsNOW! e-mail distribution list. If you would like to be removed from this list, send a message to webmaster@immunenetwork.com with the subject "Remove Me from INR's NewsNOW! Service". Do you know of anyone else who should become a list member?